Symbiotic Capital Brings Together a Global Team of Scientists, Funders and Entrepreneurs to Provide Credit Partnerships to Emerging Life Science Companies Worldwide.
Symbiotic Capital Has Closed Its Seed Fund and Has Raised Hundreds of Millions of Dollars in Credit Equity.
SCRIPTURES, Aug 6 2024 /PRNewswire/ — Symbiotic Capital (“Symbiotic”), a global life sciences debt firm, officially announced today that over $600 million with money made and intended for investments and joint investments. Symbiotic Capital is affiliated with Bellco Capital (“Bellco”), the Angels– an investment firm founded by biotechnology entrepreneur Dr. Arie Belldegrun. Symbiotic will develop and develop credit solutions for compelling life science companies to support scientific innovation across biotechnology, medical devices, diagnostics, tools, synthetic biology and other areas of healthcare. beauty.
“The life sciences industry continues to experience innovation, innovation and scientific discovery as biotechnology and technology converge,” said Symbiotic Chairman Dr. Arie Belldegrun. “As the costs of researching, developing and marketing new treatments, tools, equipment and other products have increased significantly in this sector, credit has become an important financial tool for established health businesses. . With Symbiotic Capital, we’ve created a science-first credit platform to power those jobs.”
“Over the past thirty years, Bellco’s ecosystem has partnered with visionaries across the life sciences to build and invest in compelling businesses and develop innovative laboratories and companies. “first thoughts ” for borrowers in the health care industry, “said Josh BradleyChief Investment Officer of Bellco and Symbiotic Co-Founder.
Symbiotic’s integrated scientific team includes Dr. Franz Humer (Former Chairman and CEO of Roche), Dr. Toby Cosgrove (Former President and CEO of Cleveland Clinic), UCLA experts Dr. Jim Economou and dr. Owen Wittea leading investor in the life sciences business Amy Schulman and Helen Kimand founder of an ancient life sciences company Joshua Kazam.
“Traditional financial institutions have struggled to meet the growing financial needs of growing healthcare companies due to the complexity of science and the competitive environment,” he said. Russell Goldsmith, Symbiotic Co-Chairman and former Chairman and CEO of City National Bank. “With Symbiotic Capital, we have assembled a highly skilled, multi-disciplinary and experienced team that combines the best of traditional credit writing with deep industry foundations and experience.”
As life sciences companies finance ongoing research and development, capital expenditures and business activities, debt financing can reduce the equity requirements needed for such operations and expansion.
“Credit is a more powerful tool when it is provided by a trusted partner who is connected and able to support the entire business of the borrower,” he said. Himani Bhalla, Symbiotic’s Chief Investment Officer and Co-Founder. “Symbiotic’s offerings build on the traditional benefits of credit and provide partner-driven relationships to innovative life science companies around the world.”
About Symbiotic Capital (symbcap.com)
Symbiotic Capital is a life sciences debt firm combining decades of experience across life sciences, finance and business. Our integration into the global life sciences ecosystem empowers us to provide lending solutions to fuel the growth of life sciences companies worldwide.
Life Science Credit. For Science, By Science.
For more information, please visit www.symbcap.com.
About Bellco Capital (bellcocapital.com)
Bellco Capital is an investment firm founded in 2003 by Dr. Rebecka Belldegrun, MD and Arie Belldegrun, MD Over the decades, the Bellco environment has acquired and built leading life sciences companies, invested in transformative technologies and developed innovative technologies. life sciences around the world, creating great value in the process.
For more information, please visit www.bellcocapital.com.
Names
Dan Boyle
[email protected]
Source of Symbiotic Capital
#Symbiotic #Capital #Firstofitskind #Life #Sciences #Debt #Firm #Raises #Million